MetaVia Inc. — Director's Dealing 2016

Aug 5, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Gemphire Therapeutics Inc. (GEMP)
CIK: 0001638287
Period of Report: 2016-08-04

Reporting Person: SASSINE ANDY (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$1.344	2025-05-31	Common Stock (32062)		Direct
Series A Convertible Preferred Stock	$		Common Stock (75080)		Direct
8% Convertible Subordinated Promissory Notes	$6.7059		Common Stock ()		Direct

Footnotes

F1: The options were granted on June 1, 2015, and vest in 24 equal monthly increments on the last day of each month, beginning on the date of grant.

F2: The Series A Convertible Preferred Stock has no expiration date, and shall convert into shares of common stock, par value $0.001 per share, of Gemphire Therapeutics Inc. (the "Company") on a one-for-one basis immediately prior to the closing of the Company's initial public offering.

F3: The notes were issued in the original principal amount of $200,000. The outstanding principal and accrued interest on such notes will automatically convert into shares of common stock, par value $0.001 per share, of the Company immediately prior to the closing of the Company's initial public offering. The notes bear interest at a rate of 8% per annum. The notes have accrued interest of $13,348 to date and will continue to accrue interest until conversion.